<DOC>
	<DOCNO>NCT01060904</DOCNO>
	<brief_summary>The purpose study assess safety profile brentuximab vedotin combination multi-agent chemotherapy treatment-naive Stage IIa IIb-IV Hodgkin lymphoma . It phase 1 , two-arm , open-label dose escalation study design define maximum tolerate dose , pharmacokinetics , immunogenicity anti-tumor activity brentuximab vedotin combination frontline therapy .</brief_summary>
	<brief_title>A Phase 1 Study Brentuximab Vedotin Combined With Multi-Agent Chemotherapy Hodgkin Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Treatmentnaive Hodgkin lymphoma , Stage IIa IIbIV Measurable disease least 1.5 cm Eastern Cooperative Oncology Group performance status &lt; 3 History another primary malignancy remission least 3 year Known cerebral/meningeal disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Antibodies , Monoclonal</keyword>
	<keyword>Antibody-Drug Conjugate</keyword>
	<keyword>Antigens , CD30</keyword>
	<keyword>Disease , Hodgkin</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>monomethyl auristatin E</keyword>
</DOC>